IL319844A - Compounds and compositions useful as inhibitors of iaps - Google Patents

Compounds and compositions useful as inhibitors of iaps

Info

Publication number
IL319844A
IL319844A IL319844A IL31984425A IL319844A IL 319844 A IL319844 A IL 319844A IL 319844 A IL319844 A IL 319844A IL 31984425 A IL31984425 A IL 31984425A IL 319844 A IL319844 A IL 319844A
Authority
IL
Israel
Prior art keywords
iaps
inhibitors
compounds
compositions useful
compositions
Prior art date
Application number
IL319844A
Other languages
Hebrew (he)
Original Assignee
Tract Pharmaceuticals Inc
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tract Pharmaceuticals Inc, Tufts College filed Critical Tract Pharmaceuticals Inc
Publication of IL319844A publication Critical patent/IL319844A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL319844A 2022-09-29 2023-09-29 Compounds and compositions useful as inhibitors of iaps IL319844A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263411550P 2022-09-29 2022-09-29
PCT/US2023/034219 WO2024073106A1 (en) 2022-09-29 2023-09-29 Compounds and compositions useful as inhibitors of taps

Publications (1)

Publication Number Publication Date
IL319844A true IL319844A (en) 2025-05-01

Family

ID=90479010

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319844A IL319844A (en) 2022-09-29 2023-09-29 Compounds and compositions useful as inhibitors of iaps

Country Status (8)

Country Link
EP (1) EP4593818A1 (en)
JP (1) JP2025535017A (en)
KR (1) KR20250093324A (en)
CN (1) CN120302969A (en)
AU (1) AU2023350829A1 (en)
IL (1) IL319844A (en)
MX (1) MX2025003568A (en)
WO (1) WO2024073106A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025090605A1 (en) * 2023-10-24 2025-05-01 University Of Houston System Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19
WO2025217052A1 (en) * 2024-04-08 2025-10-16 University Of Houston System Combinations of an iap inhibtor, a tyrosine kinase inhibitor and an activator of the tnf a induced cell death pathway and their use in the treatment of proliferative diseases or disorders such as cancer or pulmonary diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001234A1 (en) * 2007-04-30 2008-09-22 Genentech Inc COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF APOPTOSIS PROTEINS; AND USE IN THE TREATMENT OF CANCER.
CN108289964B (en) * 2015-08-10 2022-08-12 杭州多禧生物科技有限公司 Novel linkers and their specific conjugation for drugs and biomolecules

Also Published As

Publication number Publication date
JP2025535017A (en) 2025-10-22
WO2024073106A8 (en) 2024-11-07
EP4593818A1 (en) 2025-08-06
CN120302969A (en) 2025-07-11
WO2024073106A1 (en) 2024-04-04
AU2023350829A1 (en) 2025-04-03
MX2025003568A (en) 2025-07-01
KR20250093324A (en) 2025-06-24

Similar Documents

Publication Publication Date Title
IL318748A (en) Compositions and methods for inhibition of kras
IL319844A (en) Compounds and compositions useful as inhibitors of iaps
ZA202210224B (en) Chelator compositions for radiometals and methods of using same
IL317736A (en) Compounds as inhibitors of axl
IL321357A (en) Inhibitors of kif18a and uses thereof
IL304159A (en) Composition of bl-8040
IL321319A (en) Compounds and compositions as c-kit kinase inhibitors
SI4214210T1 (en) Compounds and compositions as sppl2a inhibitors
EP4172329A4 (en) Compositions for genome editing and methods of use thereof
IL316934A (en) Compositions and methods for inhibiting mapt expression
IL315862A (en) Angiotensinogen-modulating compositions and methods of use thereof
PT4136091T (en) Forms and compositions of inhibitors of plasma kallikrein
IL317852A (en) 3-βhsd1 inhibitors and compositions and uses thereof
HK40095943A (en) Compounds and compositions as sppl2a inhibitors
EP4153188A4 (en) Compositions and methods for inhibition of sars-cov-2 viral infections
IL323639A (en) Compounds and their uses as gpr183 inhibitors
CA3273357A1 (en) COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF
CA3273354A1 (en) COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF
GB202311665D0 (en) Modification of composition
HK40104894A (en) Compositions and methods for inhibition of kras
HK40108103A (en) Compositions comprising mixtures of compounds and uses thereof
IL324171A (en) Mivelsiran compositions and methods of use thereof
IL323920A (en) Mapt-modulating compositions and methods of use thereof
HK40109355A (en) Compositions and methods for inhibiting the expression of tmigd2
CA3276145A1 (en) Compounds and compositions as c-kit kinase inhibitors